Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
NCT06650501Phase 4Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Jan 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran etexilate oral solution in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by McGill University Health Centre. Primary endpoint: Desirability of Outcome Ranking at 90 days. Started Jan 2026; status: recruiting.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT06650501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650501.